优化亚单位疫苗可预防实验性利什曼病。
Optimized subunit vaccine protects against experimental leishmaniasis.
机构信息
Infectious Disease Research Institute, Seattle, WA 98104, USA.
出版信息
Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.
Abstract
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.
摘要
针对利什曼原虫的保护性亚单位疫苗的开发依赖于能够诱导适当免疫反应的抗原和佐剂。我们评估了第二代多蛋白抗原（Leish-110f）在不同佐剂配方中的免疫原性和针对利什曼原虫挑战的保护效果。疫苗诱导的保护与针对 Leish-110f 的抗体和 T 细胞反应相关。CD4 T 细胞是 IFN-γ、TNF 和 IL-2 双阳性和三阳性群体的来源。本研究确立了经天然（MPL-SE）或合成（EM005）Toll 样受体 4 激动剂佐剂增强的 Leish-110f 亚单位疫苗抗原的免疫原性和保护效力。
相似文献
1
Optimized subunit vaccine protects against experimental leishmaniasis.优化亚单位疫苗可预防实验性利什曼病。
Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.
2
CD4 and CD8 T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis.与 MPLA 佐剂相关的 CD4 和 CD8 T 细胞多表位嵌合蛋白可诱导美洲皮肤利什曼病的免疫预防的保护效力和长期免疫记忆。
Vaccine. 2024 Aug 30;42(21):126178. doi: 10.1016/j.vaccine.2024.126178. Epub 2024 Aug 2.
3
Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.评估Toll样受体4和7/8激动剂在BALB/c小鼠利什曼病疫苗中的佐剂作用。
Mol Immunol. 2017 Nov;91:202-208. doi: 10.1016/j.molimm.2017.09.010. Epub 2017 Sep 30.
4
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.在MPL佐剂中配制的串联连接的多亚基重组利什曼原虫疫苗（Leish-111f）的保护效力。
Vaccine. 2002 Sep 10;20(27-28):3292-303. doi: 10.1016/s0264-410x(02)00302-x.
5
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.用由T细胞抗原硫醇特异性抗氧化剂、硕大利什曼原虫应激诱导蛋白1和利什曼原虫延伸起始因子组成的多蛋白疫苗进行免疫接种可预防利什曼病。
Infect Immun. 2002 Aug;70(8):4215-25. doi: 10.1128/IAI.70.8.4215-4225.2002.
6
Total Leishmania antigens with Poly(I:C) induce Th1 protective response.利什曼原虫全抗原与聚肌胞苷酸诱导Th1保护性应答。
Parasite Immunol. 2017 Nov;39(11). doi: 10.1111/pim.12491. Epub 2017 Oct 9.
7
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.KSAC，一种明确的利什曼原虫抗原，加上佐剂，可预防其天然媒介白蛉传播的强毒力的大沙鼠利什曼原虫。
PLoS Negl Trop Dis. 2012;6(4):e1610. doi: 10.1371/journal.pntd.0001610. Epub 2012 Apr 3.
8
A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.一种特定的利什曼原虫多表位疫苗可引发 Th1 型免疫应答并预防实验性内脏利什曼病。
Cell Immunol. 2022 Oct;380:104592. doi: 10.1016/j.cellimm.2022.104592. Epub 2022 Sep 5.
9
Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.设计包含免疫原性利什曼原虫蛋白的 HLA Ⅰ类和Ⅱ类限制性表位的多表位肽，并评估治愈的皮肤利什曼病患者中诱导的 CD4+和 CD8+ T 细胞反应。
PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0008093. doi: 10.1371/journal.pntd.0008093. eCollection 2020 Mar.
10
Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.评价重组利什曼多蛋白加葡聚糖脂质 A 稳定乳剂疫苗对 C57BL/6 小鼠感染沙蝇传播的利什曼原虫的效果。
J Immunol. 2012 Nov 15;189(10):4832-41. doi: 10.4049/jimmunol.1201676. Epub 2012 Oct 8.
引用本文的文献
1
Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: A systematic review.基于嵌合或多表位抗原的疫苗预防内脏利什曼病的疗效：一项系统评价。
PLoS Negl Trop Dis. 2024 Dec 31;18(12):e0012757. doi: 10.1371/journal.pntd.0012757. eCollection 2024 Dec.
2
Advances in Vaccines: Current Development and Future Prospects.疫苗进展：当前发展与未来前景
Pathogens. 2024 Sep 20;13(9):812. doi: 10.3390/pathogens13090812.
3
Immunizing Mice with Influenza Virus-like Particles Expressing the Promastigote Surface Antigen Alleviates Inflammation in Footpad.用表达前鞭毛体表面抗原的流感病毒样颗粒免疫小鼠可减轻足垫炎症。
Vaccines (Basel). 2024 Jul 18;12(7):793. doi: 10.3390/vaccines12070793.
4
Development of a multi-epitope vaccine candidate for leishmanial parasites applying immunoinformatics and approaches.应用免疫信息学和系统生物学方法研发利什曼原虫多表位疫苗候选物
Front Immunol. 2023 Nov 15;14:1269774. doi: 10.3389/fimmu.2023.1269774. eCollection 2023.
5
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.ID93+GLA-SE结核疫苗在接种卡介苗的健康成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照的2期试验。
Infect Dis Ther. 2023 Jun;12(6):1605-1624. doi: 10.1007/s40121-023-00806-0. Epub 2023 May 11.
6
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.利什曼病疫苗：RNA技术的应用及靶向临床试验设计
Pathogens. 2022 Oct 29;11(11):1259. doi: 10.3390/pathogens11111259.
7
Design of a Chimeric Multi-Epitope Vaccine (CMEV) against Both and Parasites Using Immunoinformatic Approaches.利用免疫信息学方法设计针对两种寄生虫的嵌合多表位疫苗（CMEV）
Biology (Basel). 2022 Oct 5;11(10):1460. doi: 10.3390/biology11101460.
8
Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis.用于设计新型内脏利什曼病亚单位疫苗的免疫信息学方法
Int J Pept Res Ther. 2022;28(1):34. doi: 10.1007/s10989-021-10344-3. Epub 2021 Dec 16.
9
MPLA and AddaVax Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis.MPLA和AddaVax佐剂未能增强肌肉注射LaAg疫苗对实验性皮肤利什曼病的保护作用。
Microorganisms. 2021 Jun 11;9(6):1272. doi: 10.3390/microorganisms9061272.
10
Immunogenicity of Potential CD4 and CD8 T Cell Epitopes Derived From the Proteome of .潜在 CD4 和 CD8 T 细胞表位的免疫原性来源于. 的蛋白质组
Front Immunol. 2020 Feb 14;10:3145. doi: 10.3389/fimmu.2019.03145. eCollection 2019.
本文引用的文献
1
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.合成 TLR4 激动剂制剂的理化特性及生物学活性
Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):123-32. doi: 10.1016/j.colsurfb.2009.08.022. Epub 2009 Aug 20.
2
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.使用在乳液中配制的合成TLR4激动剂佐剂的流感病毒裂解疫苗（Fluzone）增强体液免疫和1型细胞免疫反应。
Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.
3
Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.由Ag85B-TB10.4/IC31诱导产生的针对结核分枝杆菌的保护性及多功能T细胞高度依赖于抗原剂量。
PLoS One. 2009 Jun 16;4(6):e5930. doi: 10.1371/journal.pone.0005930.
4
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.皮内免疫可提高一种新型结核疫苗候选物的保护效力。
Vaccine. 2009 May 18;27(23):3063-71. doi: 10.1016/j.vaccine.2009.03.018. Epub 2009 Mar 26.
5
Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.III型半胱氨酸蛋白酶对BALB/c小鼠的婴儿利什曼原虫感染具有保护作用，并且在内脏利什曼病患者中具有高度抗原性。
Vaccine. 2008 Oct 29;26(46):5822-9. doi: 10.1016/j.vaccine.2008.08.065. Epub 2008 Sep 18.
6
Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.评估由N-甲基葡甲胺锑酸盐（葡酸锑钠）和重组利什曼原虫110f + MPL-SE疫苗组成的免疫化疗方案治疗犬内脏利什曼病的效果。
Vaccine. 2008 Mar 17;26(12):1585-94. doi: 10.1016/j.vaccine.2008.01.026. Epub 2008 Feb 4.
7
Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs.炎症性疾病中的炎性小体：Toll样受体的作用及其与核苷酸结合寡聚化结构域样受体的相互作用
Semin Immunopathol. 2007 Sep;29(3):239-48. doi: 10.1007/s00281-007-0081-4. Epub 2007 Sep 6.
8
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.使用佐剂配制的利什曼原虫甾醇24 - 甲基转移酶对内脏利什曼病进行保护性免疫接种。
Vaccine. 2007 Oct 16;25(42):7450-8. doi: 10.1016/j.vaccine.2007.08.001. Epub 2007 Aug 20.
9
Immune response to leishmania: paradox rather than paradigm.对利什曼原虫的免疫反应：是悖论而非范例。
FEMS Immunol Med Microbiol. 2007 Nov;51(2):229-42. doi: 10.1111/j.1574-695X.2007.00311.x. Epub 2007 Aug 22.
10
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.利什-111f，一种重组多蛋白疫苗，通过激发CD4+T细胞来预防内脏利什曼病。
Infect Immun. 2007 Sep;75(9):4648-54. doi: 10.1128/IAI.00394-07. Epub 2007 Jul 2.
Zotero 插件